Meropenem Dosing for Skin and Soft Tissue Infections
For adults with normal renal function and complicated skin and soft tissue infections (cSSSI), administer meropenem 500 mg intravenously every 8 hours as a 15-30 minute infusion; however, increase the dose to 1 gram every 8 hours when Pseudomonas aeruginosa is suspected or confirmed. 1
Standard Dosing Algorithm
For Non-Pseudomonal Infections
- Dose: 500 mg IV every 8 hours
- Infusion time: 15-30 minutes
- Duration: Typically 7-14 days depending on clinical response 1
For Pseudomonal Infections
- Dose: 1 gram IV every 8 hours
- Infusion time: 15-30 minutes
- Rationale: P. aeruginosa requires higher drug exposure to achieve adequate pharmacodynamic targets 1
Renal Function Adjustments
Dosing must be reduced when creatinine clearance falls below 50 mL/min 1:
- CrCl > 50 mL/min: Standard dose (500 mg or 1 g) every 8 hours
- CrCl 26-50 mL/min: Standard dose every 12 hours
- CrCl 10-25 mL/min: Half the standard dose every 12 hours
- CrCl < 10 mL/min: Half the standard dose every 24 hours
Context from Guidelines
The IDSA guidelines for skin and soft tissue infections position meropenem as part of empiric broad-spectrum therapy for necrotizing infections (severe nonpurulent cellulitis with systemic toxicity) where polymicrobial or resistant pathogens are suspected 2. In these life-threatening scenarios, meropenem 1 gram every 8 hours is recommended as part of combination therapy with vancomycin or linezolid to cover both aerobic and anaerobic bacteria, including MRSA 2.
For non-necrotizing complicated skin infections, meropenem is appropriate when:
- Polymicrobial infection is suspected
- Gram-negative coverage (including P. aeruginosa) is needed
- Patient has failed other beta-lactam therapy
- Resistant organisms are documented or highly suspected
Critical Pitfalls to Avoid
Underdosing for Pseudomonas: The most common error is using 500 mg every 8 hours when P. aeruginosa is involved. This pathogen requires the higher 1 gram dose to achieve adequate time above MIC (fT>MIC) 1. Research demonstrates that achieving 40% fT>MIC is the minimum pharmacodynamic target, but higher targets (100% fT>MIC) correlate with better outcomes 3, 4.
Ignoring renal function: Failure to adjust for renal impairment increases seizure risk, though meropenem has a lower seizure incidence (0.1%) compared to imipenem 5, 6. Always calculate creatinine clearance using the Cockcroft-Gault equation before initiating therapy 1.
Inadequate infusion duration: While bolus injection (3-5 minutes) is FDA-approved for 1 gram doses, emerging evidence suggests prolonged infusions (3 hours) or continuous infusions may optimize pharmacodynamic target attainment, particularly in obese patients or those with augmented renal clearance 7, 8. However, the standard 15-30 minute infusion remains acceptable for most patients with normal renal function 1.
Pediatric Considerations
For children ≥3 months with cSSSI 1:
- Standard dose: 10 mg/kg every 8 hours (maximum 500 mg per dose)
- For Pseudomonas: 20 mg/kg every 8 hours (maximum 1 gram per dose)
Duration of Therapy
While not explicitly stated in the FDA label, typical treatment duration for cSSSI is 7-14 days based on clinical response, source control, and pathogen identification. Shorter courses may be appropriate for rapidly responding infections with adequate source control.